CN101316935A - 用于食管癌诊断、预后和提高生存率的方法与组合物 - Google Patents
用于食管癌诊断、预后和提高生存率的方法与组合物 Download PDFInfo
- Publication number
- CN101316935A CN101316935A CNA2006800198158A CN200680019815A CN101316935A CN 101316935 A CN101316935 A CN 101316935A CN A2006800198158 A CNA2006800198158 A CN A2006800198158A CN 200680019815 A CN200680019815 A CN 200680019815A CN 101316935 A CN101316935 A CN 101316935A
- Authority
- CN
- China
- Prior art keywords
- mirna
- level
- mir
- hsa
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 223
- 208000000461 Esophageal Neoplasms Diseases 0.000 title claims abstract description 100
- 201000004101 esophageal cancer Diseases 0.000 title claims abstract description 100
- 230000004083 survival effect Effects 0.000 title claims abstract description 85
- 238000004393 prognosis Methods 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000006872 improvement Effects 0.000 title abstract description 5
- 238000003745 diagnosis Methods 0.000 title description 47
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 198
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 194
- 108091070501 miRNA Proteins 0.000 claims abstract description 102
- 239000002679 microRNA Substances 0.000 claims abstract description 97
- 239000000523 sample Substances 0.000 claims description 312
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 175
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 175
- 238000012360 testing method Methods 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 47
- 108091068928 Homo sapiens miR-107 stem-loop Proteins 0.000 claims description 42
- 238000009396 hybridization Methods 0.000 claims description 39
- 238000001514 detection method Methods 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 230000008859 change Effects 0.000 claims description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- 108020004459 Small interfering RNA Proteins 0.000 claims description 22
- 238000004458 analytical method Methods 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000007901 in situ hybridization Methods 0.000 claims description 7
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 6
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 108091070371 Homo sapiens miR-25 stem-loop Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000000630 rising effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 108091066985 Homo sapiens miR-335 stem-loop Proteins 0.000 claims description 4
- 108091027559 Mir-96 microRNA Proteins 0.000 claims description 4
- 230000000052 comparative effect Effects 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 108091057645 miR-15 stem-loop Proteins 0.000 claims description 4
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 4
- 108091029500 miR-183 stem-loop Proteins 0.000 claims description 4
- 108091088477 miR-29a stem-loop Proteins 0.000 claims description 4
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims description 4
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims description 4
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims description 4
- 108091007432 miR-29b Proteins 0.000 claims description 4
- 108091086713 miR-96 stem-loop Proteins 0.000 claims description 4
- 108091070961 miR-96-3 stem-loop Proteins 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 230000010558 Gene Alterations Effects 0.000 claims description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 2
- 108091038720 miR-129-1 stem-loop Proteins 0.000 claims description 2
- 108091074094 miR-1291 stem-loop Proteins 0.000 claims description 2
- 239000013074 reference sample Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 238000010586 diagram Methods 0.000 claims 2
- 238000010240 RT-PCR analysis Methods 0.000 claims 1
- 239000013558 reference substance Substances 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 abstract description 616
- 230000007423 decrease Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 97
- 210000001519 tissue Anatomy 0.000 description 86
- 201000011510 cancer Diseases 0.000 description 65
- 239000003814 drug Substances 0.000 description 50
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 41
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 31
- 238000002493 microarray Methods 0.000 description 29
- 108091034117 Oligonucleotide Proteins 0.000 description 27
- 230000004069 differentiation Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- -1 methane amide Chemical class 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 108091092562 ribozyme Proteins 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000013068 control sample Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000013016 damping Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 210000003765 sex chromosome Anatomy 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- 208000035269 cancer or benign tumor Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000013545 self-assembled monolayer Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102100024682 14-3-3 protein eta Human genes 0.000 description 4
- 102100032146 Carbohydrate sulfotransferase 11 Human genes 0.000 description 4
- 102100034121 E3 ubiquitin-protein ligase RNF125 Human genes 0.000 description 4
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 description 4
- 101000775587 Homo sapiens Carbohydrate sulfotransferase 11 Proteins 0.000 description 4
- 101000711567 Homo sapiens E3 ubiquitin-protein ligase RNF125 Proteins 0.000 description 4
- 101000966875 Homo sapiens Myotubularin-related protein 4 Proteins 0.000 description 4
- 101000620662 Homo sapiens Serine/threonine-protein phosphatase 6 catalytic subunit Proteins 0.000 description 4
- 101000640315 Homo sapiens Synaptojanin-1 Proteins 0.000 description 4
- 101000674742 Homo sapiens Transcription initiation factor TFIID subunit 5 Proteins 0.000 description 4
- 102100040599 Myotubularin-related protein 4 Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 102100022345 Serine/threonine-protein phosphatase 6 catalytic subunit Human genes 0.000 description 4
- 102100033916 Synaptojanin-1 Human genes 0.000 description 4
- 102100021230 Transcription initiation factor TFIID subunit 5 Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000005357 flat glass Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010010 raising Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102100023388 ATP-dependent RNA helicase DHX15 Human genes 0.000 description 2
- 102100031836 Adhesion G-protein coupled receptor G2 Human genes 0.000 description 2
- 102100036525 Anoctamin-4 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100035683 Axin-2 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100024522 Bladder cancer-associated protein Human genes 0.000 description 2
- 102100025589 CaM kinase-like vesicle-associated protein Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100032220 Calcium and integrin-binding family member 2 Human genes 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 102100033561 Calmodulin-binding transcription activator 1 Human genes 0.000 description 2
- 102100030005 Calpain-6 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100040753 Casein kinase II subunit alpha' Human genes 0.000 description 2
- 102100030953 Cleavage and polyadenylation specificity factor subunit 4 Human genes 0.000 description 2
- 102100028908 Cullin-3 Human genes 0.000 description 2
- 102100037055 DCN1-like protein 5 Human genes 0.000 description 2
- 102100033589 DNA topoisomerase 2-beta Human genes 0.000 description 2
- 102100032883 DNA-binding protein SATB2 Human genes 0.000 description 2
- 102100036462 Delta-like protein 1 Human genes 0.000 description 2
- 102100040856 Dual specificity protein kinase CLK3 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100022457 Eukaryotic translation initiation factor 4E-binding protein 3 Human genes 0.000 description 2
- 102100025971 F-actin-capping protein subunit alpha-2 Human genes 0.000 description 2
- 102100031509 Fibrillin-1 Human genes 0.000 description 2
- 102100032523 G-protein coupled receptor family C group 5 member B Human genes 0.000 description 2
- 102100024409 Gametogenetin-binding protein 2 Human genes 0.000 description 2
- 102100037412 Germinal-center associated nuclear protein Human genes 0.000 description 2
- 101710194542 Germinal-center associated nuclear protein Proteins 0.000 description 2
- 206010060766 Heteroplasia Diseases 0.000 description 2
- 102100030309 Homeobox protein Hox-A1 Human genes 0.000 description 2
- 101000907886 Homo sapiens ATP-dependent RNA helicase DHX15 Proteins 0.000 description 2
- 101000775058 Homo sapiens Adhesion G-protein coupled receptor G2 Proteins 0.000 description 2
- 101000928366 Homo sapiens Anoctamin-4 Proteins 0.000 description 2
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 description 2
- 101000762340 Homo sapiens Bladder cancer-associated protein Proteins 0.000 description 2
- 101000932896 Homo sapiens CaM kinase-like vesicle-associated protein Proteins 0.000 description 2
- 101000943456 Homo sapiens Calcium and integrin-binding family member 2 Proteins 0.000 description 2
- 101000945309 Homo sapiens Calmodulin-binding transcription activator 1 Proteins 0.000 description 2
- 101000793671 Homo sapiens Calpain-6 Proteins 0.000 description 2
- 101000892015 Homo sapiens Casein kinase II subunit alpha' Proteins 0.000 description 2
- 101000727105 Homo sapiens Cleavage and polyadenylation specificity factor subunit 4 Proteins 0.000 description 2
- 101000916238 Homo sapiens Cullin-3 Proteins 0.000 description 2
- 101000954832 Homo sapiens DCN1-like protein 5 Proteins 0.000 description 2
- 101000655236 Homo sapiens DNA-binding protein SATB2 Proteins 0.000 description 2
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 2
- 101000749304 Homo sapiens Dual specificity protein kinase CLK3 Proteins 0.000 description 2
- 101000678288 Homo sapiens Eukaryotic translation initiation factor 4E-binding protein 3 Proteins 0.000 description 2
- 101000933166 Homo sapiens F-actin-capping protein subunit alpha-2 Proteins 0.000 description 2
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 description 2
- 101001014684 Homo sapiens G-protein coupled receptor family C group 5 member B Proteins 0.000 description 2
- 101000833430 Homo sapiens Gametogenetin-binding protein 2 Proteins 0.000 description 2
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- 101000620503 Homo sapiens LIM/homeobox protein Lhx4 Proteins 0.000 description 2
- 101000969792 Homo sapiens Metallophosphoesterase MPPED2 Proteins 0.000 description 2
- 101000936433 Homo sapiens Methylglutaconyl-CoA hydratase, mitochondrial Proteins 0.000 description 2
- 101000615261 Homo sapiens Multiple coagulation factor deficiency protein 2 Proteins 0.000 description 2
- 101000588972 Homo sapiens Myosin-1 Proteins 0.000 description 2
- 101000958753 Homo sapiens Myosin-2 Proteins 0.000 description 2
- 101000958755 Homo sapiens Myosin-4 Proteins 0.000 description 2
- 101000973259 Homo sapiens Neurogranin Proteins 0.000 description 2
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 description 2
- 101001091191 Homo sapiens Peptidyl-prolyl cis-trans isomerase F, mitochondrial Proteins 0.000 description 2
- 101001049835 Homo sapiens Potassium channel subfamily K member 3 Proteins 0.000 description 2
- 101001048456 Homo sapiens Protein Hook homolog 2 Proteins 0.000 description 2
- 101000972822 Homo sapiens Protein NipSnap homolog 2 Proteins 0.000 description 2
- 101000919288 Homo sapiens Protein disulfide isomerase CRELD1 Proteins 0.000 description 2
- 101000617778 Homo sapiens SNF-related serine/threonine-protein kinase Proteins 0.000 description 2
- 101000716740 Homo sapiens SR-related and CTD-associated factor 4 Proteins 0.000 description 2
- 101001001311 Homo sapiens Serine/threonine-protein phosphatase 4 regulatory subunit 4 Proteins 0.000 description 2
- 101001095320 Homo sapiens Serine/threonine-protein phosphatase PP1-beta catalytic subunit Proteins 0.000 description 2
- 101000851700 Homo sapiens Steroid hormone receptor ERR1 Proteins 0.000 description 2
- 101000706175 Homo sapiens Syntaxin-17 Proteins 0.000 description 2
- 101000597770 Homo sapiens Tropomodulin-1 Proteins 0.000 description 2
- 101001094573 Homo sapiens U1 small nuclear ribonucleoprotein C Proteins 0.000 description 2
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 2
- 101001070756 Homo sapiens Vasculin Proteins 0.000 description 2
- 101000743114 Homo sapiens WASH complex subunit 4 Proteins 0.000 description 2
- 101000818566 Homo sapiens Zinc finger and BTB domain-containing protein 26 Proteins 0.000 description 2
- 101000976599 Homo sapiens Zinc finger protein 423 Proteins 0.000 description 2
- 101000760250 Homo sapiens Zinc finger protein 579 Proteins 0.000 description 2
- 101000976393 Homo sapiens Zyxin Proteins 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 102100022257 LIM/homeobox protein Lhx4 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100021276 Metallophosphoesterase MPPED2 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100027392 Methylglutaconyl-CoA hydratase, mitochondrial Human genes 0.000 description 2
- 102100021387 Multiple coagulation factor deficiency protein 2 Human genes 0.000 description 2
- 102100032975 Myosin-1 Human genes 0.000 description 2
- 102100038303 Myosin-2 Human genes 0.000 description 2
- 102100038302 Myosin-4 Human genes 0.000 description 2
- 102100022159 Neurogranin Human genes 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102100022929 Nuclear receptor coactivator 6 Human genes 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100035394 POU domain, class 4, transcription factor 2 Human genes 0.000 description 2
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 102100023207 Potassium channel subfamily K member 3 Human genes 0.000 description 2
- 102100023601 Protein Hook homolog 2 Human genes 0.000 description 2
- 102100022564 Protein NipSnap homolog 2 Human genes 0.000 description 2
- 102100029371 Protein disulfide isomerase CRELD1 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100022010 SNF-related serine/threonine-protein kinase Human genes 0.000 description 2
- 102100020878 SR-related and CTD-associated factor 4 Human genes 0.000 description 2
- 102100035707 Serine/threonine-protein phosphatase 4 regulatory subunit 4 Human genes 0.000 description 2
- 102100037764 Serine/threonine-protein phosphatase PP1-beta catalytic subunit Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 2
- 102100031101 Syntaxin-17 Human genes 0.000 description 2
- 108010063400 Transcription Factor Brn-3B Proteins 0.000 description 2
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 2
- 102100035291 Tropomodulin-1 Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 102100035136 U1 small nuclear ribonucleoprotein C Human genes 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 102100034166 Vasculin Human genes 0.000 description 2
- 102100038143 WASH complex subunit 4 Human genes 0.000 description 2
- 102100021128 Zinc finger and BTB domain-containing protein 26 Human genes 0.000 description 2
- 102100023563 Zinc finger protein 423 Human genes 0.000 description 2
- 102100024724 Zinc finger protein 579 Human genes 0.000 description 2
- 102100023895 Zyxin Human genes 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 108010079292 betaglycan Proteins 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 108010051489 calin Proteins 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101150018082 U6 gene Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- CMNWUCGLNTVCSI-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].[Cl-].[O-]P([O-])([O-])=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Cl-].[O-]P([O-])([O-])=O CMNWUCGLNTVCSI-UHFFFAOYSA-J 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091023796 miR-182 stem-loop Proteins 0.000 description 1
- 108091048250 miR-182a stem-loop Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000000682 scanning probe acoustic microscopy Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
Description
Claims (54)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2006/003195 WO2008064519A1 (en) | 2006-11-28 | 2006-11-28 | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110316542.6A Division CN102399870B (zh) | 2006-11-28 | 2006-11-28 | 一种确定食道癌病人生存预后的试剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101316935A true CN101316935A (zh) | 2008-12-03 |
CN101316935B CN101316935B (zh) | 2012-02-29 |
Family
ID=39467406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800198158A Active CN101316935B (zh) | 2006-11-28 | 2006-11-28 | 一种用于诊断食道癌的芯片 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2010510769A (zh) |
CN (1) | CN101316935B (zh) |
WO (1) | WO2008064519A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101851682A (zh) * | 2010-06-25 | 2010-10-06 | 中国人民解放军南京军区南京总医院 | 一种用于检测食管鳞状细胞癌的微小核糖核酸组合及其应用 |
CN103243161A (zh) * | 2013-05-07 | 2013-08-14 | 中国医学科学院肿瘤医院 | 一种辅助预测食管鳞癌患者术后生存时间长短的产品 |
CN104034902A (zh) * | 2014-05-09 | 2014-09-10 | 赤峰学院 | 利用4个蛋白联合预测食道癌患者预后的试剂盒 |
CN104774929A (zh) * | 2015-03-18 | 2015-07-15 | 中山大学肿瘤防治中心 | miR-455-3p在食管鳞状细胞癌中的诊断、治疗和预后的应用 |
CN106459964A (zh) * | 2014-06-18 | 2017-02-22 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
CN109652545A (zh) * | 2019-01-11 | 2019-04-19 | 山西医科大学 | Znf750在筛选用于治疗食管鳞癌靶向药物中的用途 |
CN112826504A (zh) * | 2021-01-07 | 2021-05-25 | 中新国际联合研究院 | 一种游戏化的帕金森症状等级评估方法及装置 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2487253B1 (en) | 2006-01-05 | 2015-06-24 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
CN101835902B (zh) | 2007-08-03 | 2014-03-26 | 俄亥俄州立大学研究基金会 | 编码ncrna的超保守区域 |
US20100285471A1 (en) * | 2007-10-11 | 2010-11-11 | The Ohio State University Research Foundation | Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas |
CN102803511A (zh) | 2009-11-23 | 2012-11-28 | 俄亥俄州立大学 | 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法 |
GB201014049D0 (en) * | 2010-08-23 | 2010-10-06 | Sistemic Uk | Cell characterisation |
EP2637673B1 (en) | 2010-11-12 | 2016-10-26 | The Ohio State University Research Foundation | Methods related to microrna-21 and mismatch repair in colorectal cancer |
EP2640368B1 (en) | 2010-11-15 | 2020-12-30 | The Ohio State University Research Foundation | Controlled release mucoadhesive systems |
US20140031258A1 (en) * | 2011-03-28 | 2014-01-30 | The Johns Hopkins University | Serum-based mirna microarray and its use in diagnosis and treatment of barrett's esophagus (be) and esophageal adenocarcinoma (eac) |
EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHODS AND MATERIALS RELATED TO OVARIAN CANCER |
JP2015501843A (ja) | 2011-12-13 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | miR−21およびmiR−29a、エキソソーム阻害、およびがん転移に関する方法および組成物 |
CA2866052A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
WO2018025242A2 (en) * | 2016-08-04 | 2018-02-08 | Baylor Research Institute | Methods for diagnosing and treating esophageal cancer |
CN113430123A (zh) * | 2021-06-28 | 2021-09-24 | 福建医科大学 | 一种与食管鳞癌发病相关的真菌菌群及其筛选方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1150317C (zh) * | 1999-08-10 | 2004-05-19 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关新基因 |
CN1223677C (zh) * | 1999-08-10 | 2005-10-19 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关基因 |
CA2554818A1 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
-
2006
- 2006-11-28 CN CN2006800198158A patent/CN101316935B/zh active Active
- 2006-11-28 WO PCT/CN2006/003195 patent/WO2008064519A1/en active Application Filing
- 2006-11-28 JP JP2009537466A patent/JP2010510769A/ja not_active Withdrawn
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101851682B (zh) * | 2010-06-25 | 2013-08-28 | 中国人民解放军南京军区南京总医院 | 一种用于检测食管鳞状细胞癌的微小核糖核酸组合及其应用 |
CN101851682A (zh) * | 2010-06-25 | 2010-10-06 | 中国人民解放军南京军区南京总医院 | 一种用于检测食管鳞状细胞癌的微小核糖核酸组合及其应用 |
CN103243161A (zh) * | 2013-05-07 | 2013-08-14 | 中国医学科学院肿瘤医院 | 一种辅助预测食管鳞癌患者术后生存时间长短的产品 |
CN103243161B (zh) * | 2013-05-07 | 2015-02-25 | 中国医学科学院肿瘤医院 | 一种辅助预测食管鳞癌患者术后生存时间长短的产品 |
CN104034902B (zh) * | 2014-05-09 | 2015-11-25 | 赤峰学院 | 利用4个蛋白联合预测食道癌患者预后的试剂盒 |
CN104034902A (zh) * | 2014-05-09 | 2014-09-10 | 赤峰学院 | 利用4个蛋白联合预测食道癌患者预后的试剂盒 |
CN111910002A (zh) * | 2014-06-18 | 2020-11-10 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
CN106459964A (zh) * | 2014-06-18 | 2017-02-22 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
US10619212B2 (en) | 2014-06-18 | 2020-04-14 | Toray Industries, Inc. | Esophageal cancer detection kit or device, and detection method |
CN106459964B (zh) * | 2014-06-18 | 2020-08-21 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
US11542558B2 (en) | 2014-06-18 | 2023-01-03 | Toray Industries, Inc. | Esophageal cancer detection kit or device, and detection method |
CN111910002B (zh) * | 2014-06-18 | 2024-04-12 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
CN104774929B (zh) * | 2015-03-18 | 2017-06-30 | 中山大学肿瘤防治中心 | miR‑455‑3p在食管鳞状细胞癌中的诊断、治疗和预后的应用 |
CN104774929A (zh) * | 2015-03-18 | 2015-07-15 | 中山大学肿瘤防治中心 | miR-455-3p在食管鳞状细胞癌中的诊断、治疗和预后的应用 |
CN109652545A (zh) * | 2019-01-11 | 2019-04-19 | 山西医科大学 | Znf750在筛选用于治疗食管鳞癌靶向药物中的用途 |
CN112826504A (zh) * | 2021-01-07 | 2021-05-25 | 中新国际联合研究院 | 一种游戏化的帕金森症状等级评估方法及装置 |
CN112826504B (zh) * | 2021-01-07 | 2024-03-26 | 中新国际联合研究院 | 一种游戏化的帕金森症状等级评估方法及装置 |
Also Published As
Publication number | Publication date |
---|---|
WO2008064519A1 (en) | 2008-06-05 |
CN101316935B (zh) | 2012-02-29 |
JP2010510769A (ja) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101316935B (zh) | 一种用于诊断食道癌的芯片 | |
CN101842484B (zh) | 人外周血微泡中的mirna表达和其用途 | |
CN101835902B (zh) | 编码ncrna的超保守区域 | |
CN102533966B (zh) | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 | |
Chen et al. | Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis | |
CN102439169B (zh) | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 | |
CN102272330B (zh) | 用于肺癌诊断、预后和提高生存率的试剂盒 | |
US20090306181A1 (en) | Compositions and methods for evaluating and treating heart failure | |
CN102007408A (zh) | 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途 | |
CN101939446A (zh) | 人类卵巢癌中的微小rna特征 | |
CN103937876A (zh) | 用于诊断和治疗食管腺癌的方法和组合物 | |
CN103555825A (zh) | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 | |
CN102892897A (zh) | 用于肺癌的微rna表达谱分析的组合物和方法 | |
CN102985558A (zh) | 用于肝细胞癌症的微rna表达谱分析的组合物和方法 | |
WO2014169226A2 (en) | Methods of diagnosing and treating chronic pain | |
CN102399870B (zh) | 一种确定食道癌病人生存预后的试剂 | |
Ding et al. | The emerging role of small non-coding RNA in renal cell carcinoma | |
US20210404002A1 (en) | Quantitative Algorithm for Endometriosis | |
CN110042164B (zh) | 肺癌诊疗用lncRNA标志物 | |
CN103180461A (zh) | 用于间皮瘤预后的组合物和方法 | |
CN102510905B (zh) | 用于宫颈上皮内瘤样病变和宫颈癌的诊断和预后的方法与组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CAPITALBIO CORPORATION CO., LTD. Free format text: FORMER NAME: CAPITALBIO CORPORATION |
|
CP01 | Change in the name or title of a patent holder |
Address after: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee after: CAPITALBIO CORPORATION Patentee after: Tsinghua University Patentee after: Tumour Inst., China Medical Science Research Academy Address before: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee before: Capitalbio Corporation Patentee before: Tsinghua University Patentee before: Tumour Inst., China Medical Science Research Academy |